MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes

Area of Science:

• Cell Biology
• Endocrinology
• Molecular Medicine

Background:

• Apoptotic cell death of insulin-producing beta cells is central to diabetes mellitus.
• Existing treatments cannot prevent the loss of functional beta cell mass.
• New strategies are needed to prevent beta cell apoptosis and dysfunction.

Purpose of the Study:

• Identify critical regulators of beta cell apoptosis and dysfunction in diabetes.
• Investigate the role of mammalian sterile 20-like kinase-1 (MST1) in beta cell death.
• Explore MST1 as a potential therapeutic target for diabetes.

Main Methods:

• Assessed MST1 activation in human and mouse islets under diabetogenic conditions.
• Examined MST1's role in the mitochondrial apoptosis pathway via BIM upregulation.
• Investigated MST1-mediated phosphorylation and degradation of PDX1.
• Evaluated the effects of MST1 deficiency on beta cell function and survival in vitro and in vivo.

Main Results:

• MST1 was activated in beta cells during diabetes, inducing apoptosis through the BIM-mediated mitochondrial pathway.
• MST1 phosphorylated and degraded the transcription factor PDX1, impairing insulin secretion.
• MST1 deficiency fully restored normoglycemia, beta cell function, and survival.
• MST1 acts as a proapoptotic kinase and key mediator of beta cell dysfunction.

Conclusions:

• MST1 is a critical mediator of beta cell apoptosis and dysfunction in diabetes.
• Targeting MST1 may offer a novel therapeutic strategy for diabetes treatment.
• Preventing MST1 activation could preserve beta cell mass and function.